Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROPION-Lung17: Datopotamab Deruxtecan vs Docetaxel in Advanced Non-squamous NSCLC
NCT07291037Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Oct 2025
- Primary completion
- Jan 2029
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 21
01
Overview
A Phase 3 trial of datopotamab deruxtecan in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started Oct 2025; status: recruiting.
02
Drugs
datopotamab deruxtecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07291037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07291037.